

Federico Cappuzzo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5408729/federico-cappuzzo-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

266
papers

28,768
citations

66
h-index

168
g-index

304
ext. papers

33,369
ext. citations

5.6
avg, IF

6.47
L-index

#	Paper	IF	Citations
266	KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously".. <i>Journal of Thoracic Oncology</i> , 2022 , 17, e40-e41	8.9	1
265	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211059873	5.4	1
264	Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2021 ,	4.5	7
263	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	17
262	COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience. <i>Breast Journal</i> , 2021 , 27, 359-362	1.2	3
261	Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma. <i>Oral Oncology</i> , 2021 , 115, 105133	4.4	0
260	Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
259	The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 669839	5.3	1
258	IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1909-1924	8.9	37
257	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103176	7	6
256	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2065-2077	8.9	6
255	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3713-3736	4.4	0
254	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1547-1558	8.9	30
253	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2021 , 22, 1438-1447	21.7	18
252	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.. <i>Thoracic Cancer</i> , 2021 ,	3.2	2
251	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). <i>Annals of Oncology</i> , 2020 , 31, S1078	10.3	2
250	1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial. <i>Annals of Oncology</i> , 2020 , 31, S814-S815	10.3	5

249	1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations. <i>Annals of Oncology</i> , 2020 , 31, S817-S818	10.3	9
248	1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations. <i>Annals of Oncology</i> , 2020 , 31, S837-S838	10.3	7
247	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 . <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2209-2221	7.4	32
246	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020 , 21, 498-508.e2	4.9	27
245	Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. <i>Expert Review of Respiratory Medicine</i> , 2020 , 14, 565-576	3.8	5
244	Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate?. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e92-e93	8.9	
243	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. <i>Radiotherapy and Oncology</i> , 2020 , 149, 84-88	5.3	5
242	Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1351-1360	8.9	160
241	How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease. <i>Translational Lung Cancer Research</i> , 2020 , 9, 2686-2695	4.4	2
240	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. <i>Future Oncology</i> , 2020 , 16, 1433-1439	3.6	8
239	Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. <i>Clinical and Translational Oncology</i> , 2020 , 22, 294-301	3.6	1
238	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020 , 12,	6.6	11
237	A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens. <i>Cancer Cytopathology</i> , 2020 , 128, 928-938	3.9	7
236	Blockage of interleukin-1 β with canakinumab in patients with Covid-19. <i>Scientific Reports</i> , 2020 , 10, 21775	4.9	33
235	ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). <i>Clinical Lung Cancer</i> , 2020 , 21, 15-20	4.9	34
234	Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. <i>Anticancer Research</i> , 2020 , 40, 983-990	2.3	9
233	Crizotinib in and Deregulated NSCLC-Response. <i>Clinical Cancer Research</i> , 2020 , 26, 1775	12.9	2
232	Crizotinib in -Deregulated or -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 7312-7319	12.9	80

231	Chemoimmunotherapy for stage IV non-small-cell lung cancer - AuthorsReply. <i>Lancet Oncology, The</i> , 2019 , 20, e467	21.7	
230	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib. <i>Cancers</i> , 2019 , 11,	6.6	4
229	The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. <i>Translational Lung Cancer Research</i> , 2019 , 8, 429-449	4.4	29
228	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019 , 133, 163-166	5.3	19
227	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 924-937	21.7	562
226	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019 , 135, 74-77	5.3	9
225	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program 2019 , 7, 99		71
224	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. <i>Lancet Respiratory Medicine, the</i> , 2019 , 7, 387-401	35.1	398
223	Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. <i>Oncotarget</i> , 2019 , 10, 561-572	3.3	7
222	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019 , 123, 98-105	5.6	48
221	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). <i>Tumori</i> , 2019 , 105, 3-14	1.7	6
220	Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial. <i>Annals of Oncology</i> , 2019 , 30, v609-v610	10.3	3
219	ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9121-TPS9121	2.2	1
218	The interplay between PD-L1 and vimentin in NSCLC patients: An exploratory analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20688-e20688	2.2	
217	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. <i>Oncologist</i> , 2019 , 24, e1165-e1171	5.7	23
216	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 2019 , 7, 316		56
215	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 129, 35-40	5.9	77
214	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. <i>British Journal of Cancer</i> , 2019 , 120, 57-62	8.7	40

213	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. <i>Clinical Lung Cancer</i> , 2019 , 20, e186-e194	4.9	27
212	Deregulation in Lung Cancer: Right Time to Adopt an Orphan?. <i>Clinical Cancer Research</i> , 2018 , 24, 2470-2479	4.7	5
211	Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. <i>Future Oncology</i> , 2018 , 14, 1477-1486	3.6	14
210	Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 77-86	3.5	9
209	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. <i>European Journal of Cancer</i> , 2018 , 100, 126-134	3.4	65
208	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. <i>New England Journal of Medicine</i> , 2018 , 378, 2288-2301	59.2	1695
207	Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9002-9002	2.2	59
206	IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, LBA9000-LBA9000	2.2	136
205	Lung Cancer Update 2017: from the test tube to the bed. <i>Annals of Translational Medicine</i> , 2018 , 6, 86	3.2	
204	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. <i>Journal of Thoracic Disease</i> , 2018 , 10, 3909-3921	2.6	24
203	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2018 , 9, 17554-17563	3.3	16
202	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2251-2258	2.2	197
201	How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. <i>Journal of Thoracic Disease</i> , 2018 , 10, 3883-3890	2.6	1
200	Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. <i>Tumor Biology</i> , 2018 , 40, 1010428318815047	2.9	4
199	The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer. <i>Science Signaling</i> , 2017 , 10,	8.8	28
198	P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1296-S1297	8.9	3
197	P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1336-S1337	8.9	2
196	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Translational Lung Cancer Research</i> , 2017 , 6, 373-386	4.4	32

195	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2017 , 112, 181-187	5.9	28
194	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 15-26	8.9	186
193	Treating mutation resistance in non-small cell lung cancer - role of osimertinib. <i>The Application of Clinical Genetics</i> , 2017 , 10, 49-56	3.1	18
192	MET exon 14 mutations in advanced lung adenocarcinoma: Frequency and coexisting alterations.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20656-e20656	2.2	1
191	Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. <i>Oncotarget</i> , 2017 , 8, 13611-13619	3.3	66
190	Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20676-e20676	2.2	
189	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 176-87	5.4	22
188	Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. <i>Lung Cancer</i> , 2016 , 93, 95-103	5.9	34
187	Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 203-14	3.8	5
186	Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 545-555	8.9	63
185	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. <i>Annals of Oncology</i> , 2016 , 27, 281-6	10.3	187
184	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. <i>ESMO Open</i> , 2016 , 1, e000118	6	4
183	Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9079-9079	2.2	3
182	Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS9103-TPS9103	2.2	
181	Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC. <i>Translational Lung Cancer Research</i> , 2016 , 5, 579-587	4.4	5
180	Minimizing Aircraft ECS Bleed Off-Take - Virtual Integrated Aircraft Applications. <i>SAE International Journal of Aerospace</i> , 2016 , 9, 151-162	0.3	3
179	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016 , 99, 31-7	5.9	25
178	PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program. <i>Journal of Thoracic Oncology</i> , 2016 , 11, S302-S303	8.9	5

177	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2858-65 ^{2.2}	171
176	cMET Exon 14 Skipping: From the Structure to the Clinic. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1423-328.9	38
175	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016 , 27, 1291-8	10.3 91
174	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. <i>Drugs</i> , 2016 , 76, 831-40	12.1 11
173	EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. <i>Oncology Reports</i> , 2016 , 36, 1166-72	3.5 14
172	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology, The</i> , 2015 , 16, 257-65	21.7 1050
171	Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study. <i>PLoS ONE</i> , 2015 , 10, e0125037	3.7 7
170	Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. <i>Journal of Clinical Oncology</i> , 2015 , 33, 992-9	2.2 266
169	Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 665-72	8.9 22
168	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015 , 64, 921-8	19.2 17
167	Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. <i>Lung Cancer</i> , 2015 , 90, 234-42	5.9 10
166	Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly. <i>Drugs and Aging</i> , 2015 , 32, 907-16	4.7 8
165	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. <i>British Journal of Cancer</i> , 2015 , 112, 95-102	8.7 407
164	cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. <i>Cancers</i> , 2015 , 7, 556-73	6.6 29
163	Experience with erlotinib in the treatment of non-small cell lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2015 , 9, 146-63	4.9 19
162	microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 14924-9 ^{11.5}	61
161	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. <i>Lung Cancer</i> , 2015 , 87, 89-95	5.9 33
160	Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8101-8101	2.2 4

159	Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. <i>Annals of Translational Medicine</i> , 2015 , 3, 32	3.2	
158	Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. <i>Translational Lung Cancer Research</i> , 2015 , 4, 465-74	4.4	16
157	Resistance to anti-angiogenic drugs and therapeutic options 2015 , 61-66		
156	Overcoming EGFR-TKI Resistance 2015 , 37-50		
155	Resistance to EGFR TKIs 2015 , 27-36		
154	Therapy options for advanced NSCLC 2015 , 5-25		
153	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11076-11076	2.2	
152	Protein kinase inhibitors to treat non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1203-13	4	16
151	Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. <i>Cancer Cytopathology</i> , 2014 , 122, 445-53	3.9	38
150	A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014 , 25, 2156-2162	10.3	22
149	Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. <i>Clinical Lung Cancer</i> , 2014 , 15, 470-479	4.9	12
148	Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. <i>Clinical Lung Cancer</i> , 2014 , 15, 411-417.e4	4.9	28
147	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1783-93	4.9	7
146	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014 , 5, 3518	17.4	173
145	Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014 , 15, 173-81	4.9	50
144	Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. <i>Clinical Lung Cancer</i> , 2014 , 15, 338-45.e1	4.9	6
143	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <i>Lancet, The</i> , 2014 , 384, 665-73	40	799
142	First-Line Crizotinib Vs Pemetrexed + Cisplatin/Carboplatin in Asian Patients with Advanced Alk+ Nslc in Profile 1014. <i>Annals of Oncology</i> , 2014 , 25, v2	10.3	3

141	The Role of ERBB Family Blockade in NSCLC. <i>The Journal of Oncopathology</i> , 2014 , 2, 51-58		
140	Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2014 , 5, 43-50	2.9	1
139	Management of NSCLC: focus on crizotinib. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2587-97	4	13
138	HER2 in solid tumors: more than 10 years under the microscope; where are we now?. <i>Future Oncology</i> , 2014 , 10, 1469-86	3.6	31
137	First-line crizotinib versus chemotherapy in ALK-positive lung cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 2167-77	59.2	2116
136	ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. <i>Archives of Pathology and Laboratory Medicine</i> , 2014 , 138, 1448-58	5	73
135	Pharmacotherapy targeting the EGFR oncogene in NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2293-305	4	16
134	MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 37-45.e4	3.8	41
133	Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. <i>Translational Respiratory Medicine</i> , 2014 , 2, 2		19
132	Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11035-11035	2.2	4
131	First-line crizotinib versus pemetrexed+isplatin or pemetrexed+carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). <i>Journal of Clinical Oncology</i> , 2014 , 32, 8002-8002	2.2	30
130	Targeting MET in NSCLC: looking for a needle in a haystack. <i>Translational Lung Cancer Research</i> , 2014 , 3, 389-91	4.4	7
129	The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?. <i>Current Drug Targets</i> , 2014 , 15, 1284-92	3	8
128	Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11056-11056	2.2	
127	Predictive and Prognostic Implications of EGFR Mutations 2014 , 25-30		
126	The Human Epidermal Growth Factor Receptor (HER) Family: Structure and Function 2014 , 7-17		
125	EGFR-Targeted Therapies in Non-small Cell Lung Cancer 2014 , 31-66		
124	Ceritinib for the treatment of non-small cell lung cancer. <i>Drugs of Today</i> , 2014 , 50, 465-73	2.5	

123	Targeted therapy for NSCLC with driver mutations. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1401-1424	3.4	33
122	Strategies for improving outcomes in NSCLC: a look to the future. <i>Lung Cancer</i> , 2013 , 82, 375-82	5.9	26
121	HER2 and lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 1219-28	3.5	50
120	Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. <i>BJU International</i> , 2013 , 111, 44-52	5.6	55
119	Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. <i>Lung Cancer</i> , 2013 , 82, 231-7	5.9	58
118	Erlotinib in the first-line treatment of non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 523-33	3.5	15
117	Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. <i>International Journal of Oncology</i> , 2013 , 43, 765-74	4.4	48
116	Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. <i>Current Opinion in Oncology</i> , 2013 , 25, 130-6	4.2	29
115	HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2013 , 108, 668-75	8.7	109
114	Rare mutations in non-small-cell lung cancer. <i>Future Oncology</i> , 2013 , 9, 699-711	3.6	17
113	Epidermal growth factor receptor inhibition in lung cancer: status 2012. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 373-84	8.9	99
112	MET overexpression and gene amplification in NSCLC: a clinical perspective. <i>Lung Cancer: Targets and Therapy</i> , 2013 , 4, 15-25	2.9	5
111	Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. <i>Biologics: Targets and Therapy</i> , 2013 , 7, 61-8	4.4	26
110	Irreversible EGFR-TKIs: dreaming perfection. <i>Translational Lung Cancer Research</i> , 2013 , 2, 40-9	4.4	19
109	Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11058-11058	2.2	
108	Micro-RNA signature differences in lung adenocarcinoma with specific driver alterations.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11066-11066	2.2	
107	First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly frail patients with advanced non-small-cell lung cancer: a multicenter phase II study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 2003-8	4.9	2
106	Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 4570-9	12.9	326

105	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. <i>Cancer Treatment Reviews</i> , 2012 , 38, 416-30	14.4	97
104	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012 , 44, 1104-10	36.3	919
103	Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. <i>Lung Cancer</i> , 2012 , 76, 269-79	5.9	20
102	Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. <i>Drugs</i> , 2012 , 72 Suppl 1, 28-36	12.1	54
101	Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. <i>British Journal of Cancer</i> , 2012 , 107, 793-9	8.7	90
100	K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value 2012 , 2012, 837306		22
99	Emerging drugs for small cell lung cancer--an update. <i>Expert Opinion on Emerging Drugs</i> , 2012 , 17, 31-6	3.7	19
98	The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. <i>Journal of Clinical Pathology</i> , 2012 , 65, 1-7	3.9	27
97	Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 670-677	10.3	38
96	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. <i>Journal of Clinical Pathology</i> , 2012 , 65, 218-23	3.9	29
95	Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. <i>Annals of Oncology</i> , 2012 , 23, 388-94	10.3	76
94	p95HER2 truncated form in resected non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 520-7	8.9	14
93	Use of HER2 gene amplification to identify patients with metastatic colorectal cancer resistant to anti-EGFR monoclonal antibodies.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 474-474	2.2	3
92	Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?. <i>Journal of Thoracic Disease</i> , 2012 , 4, 226-8	2.6	2
91	EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMATION. <i>Translational Lung Cancer Research</i> , 2012 , 1, 160-2	4.4	
90	MYC gene copy number (GCN) and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e21018-e21018	2.2	
89	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. <i>Lung Cancer</i> , 2011 , 71, 249-57	5.9	92
88	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. <i>Lung Cancer</i> , 2011 , 72, 3-8	5.9	35

87	Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4113-20	2.2	244
86	Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 395-6	8.9	35
85	Gefitinib for non-small-cell lung cancer treatment. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 987-96	4.1	11
84	Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4789-95	2.2	134
83	Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. <i>Science Translational Medicine</i> , 2011 , 3, 99ra86	17.5	463
82	Consequences of targeted treatments for second-line therapy. <i>Annals of Oncology</i> , 2010 , 21 Suppl 7, vii234-40	10.3	4
81	Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. <i>Annals of Oncology</i> , 2010 , 21, 562-567	10.3	64
80	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. <i>Science Translational Medicine</i> , 2010 , 2, 62ra93	17.5	646
79	Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. <i>Oncologist</i> , 2010 , 15, 1102-12	5.7	56
78	Clinical implications of MET gene copy number in lung cancer. <i>Future Oncology</i> , 2010 , 6, 239-47	3.6	47
77	Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature?. <i>Human Pathology</i> , 2010 , 41, 614-5; author reply 615-616	3.7	
76	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , 2010 , 11, 521-9	21.7	982
75	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , 2010 , 11, 753-62	21.7	1653
74	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1706-13	8.9	237
73	Impact of biomarkers on non-small cell lung cancer treatment. <i>Targeted Oncology</i> , 2010 , 5, 5-17	5	14
72	Gemcitabine for the treatment of advanced nonsmall cell lung cancer. <i>OncoTargets and Therapy</i> , 2009 , 2, 209-17	4.4	12
71	Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5620-6	2.2	76
70	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. <i>Annals of Oncology</i> , 2009 , 20, 1674-81	10.3	134

69	EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. <i>Journal of Clinical Pathology</i> , 2009 , 62, 970-7	3.9	94
68	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2009 , 20, 298-304	10.3	243
67	Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. <i>Oncogene</i> , 2009 , 28 Suppl 1, S32-7	9.2	202
66	Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1667-74	2.2	456
65	Emerging drugs for small-cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2009 , 14, 591-606	3.7	18
64	Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. <i>Neoplasia</i> , 2009 , 11, 1084-92	6.4	76
63	New targeted therapies for non-small-cell lung cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2009 , 6, 335-350		4
62	MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 472-8	8.9	41
61	Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. <i>British Journal of Cancer</i> , 2008 , 99, 83-9	8.7	155
60	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. <i>British Journal of Cancer</i> , 2008 , 99, 51-6	8.7	93
59	Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. <i>Lung Cancer</i> , 2008 , 59, 355-63	5.9	137
58	EGFR FISH versus mutation: different tests, different end-points. <i>Lung Cancer</i> , 2008 , 60, 160-5	5.9	39
57	Primary pulmonary meningioma: report of a case and review of the literature. <i>Lung Cancer</i> , 2008 , 62, 401-7	5.9	51
56	Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4253-60	2.2	191
55	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. <i>Targeted Oncology</i> , 2008 , 3, 173-186	5	3
54	Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. <i>Cancer</i> , 2008 , 112, 1555-61	6.4	77
53	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. <i>Annals of Oncology</i> , 2008 , 19, 717-23	10.3	225
52	Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S12-4	8.9	6

51	MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. <i>Science</i> , 2007 , 316, 1039-43	33.3	3705
50	Is gemcitabine cost effective in cancer treatment?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007 , 7, 239-49	2.2	1
49	Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. <i>Annals of Oncology</i> , 2007 , 18 Suppl 9, ix150-5	10.3	12
48	Optimizing Anti-EGFR Strategies in Cancer Treatment. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 267-275	0.4	
47	Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Oncologist</i> , 2007 , 12, 211-20	5.7	43
46	EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007 , 2, 423-9	8.9	68
45	C1-04: A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I). <i>Journal of Thoracic Oncology</i> , 2007 , 2, S359-S360	8.9	5
44	M03-02: Molecular predictors for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): role of egfr gene amplification. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S156-S157	8.9	1
43	Assessment of tumor response in malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2007 , 33, 533-41	14.4	50
42	Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2248-55	2.2	198
41	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. <i>Annals of Oncology</i> , 2007 , 18, 752-60	10.3	232
40	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. <i>Expert Opinion on Medical Diagnostics</i> , 2007 , 1, 183-91		2
39	Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 3078-84	12.9	85
38	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. <i>Annals of Oncology</i> , 2006 , 17 Suppl 2, ii42-45	10.3	23
37	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. <i>Annals of Oncology</i> , 2006 , 17, 1120-7	10.3	75
36	HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2006 , 354, 2619-21	59.2	183
35	A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. <i>Lung Cancer</i> , 2006 , 52, 319-25	5.9	28
34	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S13-S19	8.9	36

33	Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). <i>Reviews on Recent Clinical Trials</i> , 2006 , 1, 1-13	1.2	38
32	Clinical experience with gefitinib: an update. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 58, 31-45	7	46
31	Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 95, 45-53	4.4	30
30	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S13-S19	8.9	100
29	Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S13-9	8.9	30
28	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5007-18	2.2	333
27	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 643-55	9.7	1367
26	Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3279-87	2.2	223
25	Role of gemcitabine in cancer therapy. <i>Future Oncology</i> , 2005 , 1, 7-17	3.6	213
24	Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2005 , 93, 29-34	8.7	25
23	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. <i>British Journal of Cancer</i> , 2005 , 93, 1334-40	8.7	70
22	RESPONSE: Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 462-463	9.7	1
21	Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 461-2; author reply 462-3	9.7	3
20	Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. <i>Annals of Oncology</i> , 2004 , 15, 1042-7	10.3	281
19	Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1133-41	9.7	333
18	Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 6006-12	12.9	36
17	Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1795; author reply 1795-6	9.7	
16	Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). <i>British Journal of Cancer</i> , 2004 , 90, 82-6	8.7	46

15	Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. <i>British Journal of Cancer</i> , 2004 , 90, 31-5	8.7	65
14	Emerging drugs for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2003 , 8, 179-92	3.7	8
13	Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study. <i>Cancer</i> , 2003 , 98, 128-34	6.4	37
12	ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. <i>British Journal of Cancer</i> , 2003 , 89, 246-7	8.7	40
11	Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2003 , 41, 227-31	5.9	105
10	Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2003 , 42, 355-61	5.9	14
9	Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2658-63	2.2	192
8	Present and future treatment of advanced non-small cell lung cancer. <i>Seminars in Oncology</i> , 2002 , 29, 9-16	5.5	12
7	Gemcitabine in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 745-53	4	8
6	Multimodality therapy for non-small cell lung cancer (NSCLC): ongoing Italian experiences in the adjuvant and neoadjuvant settings. <i>Lung Cancer</i> , 2001 , 34 Suppl 3, S45-7	5.9	
5	Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study. <i>Nutrition</i> , 1997 , 13, 748-51	4.8	62
4	Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. <i>Journal of Clinical Oncology</i> , 1996 , 14, 2546-51	2.2	117
3	Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 1995 , 13, 2613-9	2.2	39
2	Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. <i>Oncology</i> , 1995 , 52, 454-7	3.6	5
1	Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$		1